 |
|
|
| |
Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: 96-Week Update from a Blinded Phase 3 Study
|
| |
| |
CROI 2026 Denver Feb 22-25
Amy E. Colson, MD, MPH1; Anthony M. Mills, MD2; Moti Ramgopal, MD3; Christopher Bettacchi, MD4; Olayemi Osiyemi, MD5; Federico Hinestrosa, MD6; Gordon Crofoot, MD7; Harold P. Katner, MD8; Hiroyuki Gatanaga, MD9; Margaret Johnson, MD10; Chenguang Zhang, PhD11; Tracy L. Diamond, PhD11; Erika Barninger, BS11; Michelle C. Fox, MD11; Mengchun Li, MD11
1Community Resource Initiative, Boston, MA and Cambridge Health Alliance, Cambridge, MA, USA; 2Men’s Health Foundation, Los Angeles, CA, USA; 3Midway Immunology and Research Center, Fort Pierce, FL, USA; 4HIV Center, North Texas Infectious Diseases Consultants, Dallas, TX, USA; 5Triple O Research Institute, West Palm Beach, FL, USA; 6Orlando Immunology Center, Orlando, Florida, USA; 7The Crofoot Research Center, Inc., Houston, TX, USA; 8Mercer University School of Medicine, Macon, GA, USA; 9AIDS Clinical Center, NCGM, Tokyo, Japan; 10Royal Free London NHS Foundation Trust, London, UK; 11Merck & Co., Inc., Rahway, NJ, USA
|
| |
|
|
|
|
|
